Burcugül Kaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Burcugül Kaya has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Derya Yıldırım
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey
6 shared publications - Hamit Küçük
Division of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Türkiye
6 shared publications - Mehmet Akif Öztürk
Division of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Türkiye
6 shared publications - Rıza Can Kardaş
Division of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Türkiye
6 shared publications - Abdulsamet Erden
Division of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Türkiye
5 shared publications - Berna Göker
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey
5 shared publications
Latest Publications
- 12 June 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (7)
Glomerulonephritis in Takayasu arteritis is dominated by mesangial and AA amyloid lesions and often arises during remission: a case-based review
Takayasu arteritis (TAK) is a large-vessel vasculitis in which glomerulonephritis is a rare complication with a poorly characterized clinical and histopathological profile. Patients with biopsy-proven glomerulonephritis were retrospectively identified from a single-center TAK cohort followed between 2014 and 2022. A systematic review of PubMed/MEDLINE, Scopus, and Web of Science for articles published up to December 2025 was conducted in parallel, excluding studies involving patients younger than 18 years and cases with confounding autoimmune conditions or non-classifiable biopsy findings. This case-based review was reported in accordance with the CABARET and PRISMA 2020 standards. Among 72 patients with TAK, three (4.2%) had biopsy-proven glomerulonephritis. The systematic review yielded 31 articles describing 39 additional cases (84.6% female; median age at TAK diagnosis 26 years; median age at glomerular disease diagnosis 33 years). Glomerular disease was diagnosed a median of 5 years (IQR 0-11) after TAK and most often presented as asymptomatic proteinuria or nephrotic syndrome. Mesangial proliferative glomerulonephritis was the most common subtype (35.9%), followed by AA amyloidosis (30.8%), membranoproliferative glomerulonephritis (12.8%), focal segmental glomerulosclerosis (10.3%), and membranous nephropathy (7.7%). Renal artery stenosis was absent in 69.2% of cases. Corticosteroids were used in 92.3% of cases and biologic agents in 10.3%. Glomerulonephritis is a rare but clinically significant late complication of TAK, characterized by a distinct histopathological spectrum dominated by mesangial lesions, AA amyloidosis, and membranoproliferative glomerulonephritis. Routine proteinuria screening in patients with TAK, including during clinical remission, is warranted to enable early detection and timely management.
- 12 June 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (7)
Glomerulonephritis in Takayasu arteritis is dominated by mesangial and AA amyloid lesions and often arises during remission: a case-based review
Takayasu arteritis (TAK) is a large-vessel vasculitis in which glomerulonephritis is a rare complication with a poorly characterized clinical and histopathological profile. Patients with biopsy-proven glomerulonephritis were retrospectively identified from a single-center TAK cohort followed between 2014 and 2022. A systematic review of PubMed/MEDLINE, Scopus, and Web of Science for articles published up to December 2025 was conducted in parallel, excluding studies involving patients younger than 18 years and cases with confounding autoimmune conditions or non-classifiable biopsy findings. This case-based review was reported in accordance with the CABARET and PRISMA 2020 standards. Among 72 patients with TAK, three (4.2%) had biopsy-proven glomerulonephritis. The systematic review yielded 31 articles describing 39 additional cases (84.6% female; median age at TAK diagnosis 26 years; median age at glomerular disease diagnosis 33 years). Glomerular disease was diagnosed a median of 5 years (IQR 0-11) after TAK and most often presented as asymptomatic proteinuria or nephrotic syndrome. Mesangial proliferative glomerulonephritis was the most common subtype (35.9%), followed by AA amyloidosis (30.8%), membranoproliferative glomerulonephritis (12.8%), focal segmental glomerulosclerosis (10.3%), and membranous nephropathy (7.7%). Renal artery stenosis was absent in 69.2% of cases. Corticosteroids were used in 92.3% of cases and biologic agents in 10.3%. Glomerulonephritis is a rare but clinically significant late complication of TAK, characterized by a distinct histopathological spectrum dominated by mesangial lesions, AA amyloidosis, and membranoproliferative glomerulonephritis. Routine proteinuria screening in patients with TAK, including during clinical remission, is warranted to enable early detection and timely management.
- 28 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Assessment of interstitial lung disease in systemic sclerosis using oscillometric methods: a novel approach to respiratory assessment
Objectives: Cardiopulmonary involvement is the leading cause of mortality in SSc, and early detection of interstitial lung disease (ILD) is critical to improving outcomes. Conventional spirometry has limitations, whereas impulse oscillometry (IOS) could provide a non-invasive, effort-independent method to detect and monitor pulmonary involvement in these patients. We aimed to evaluate IOS parameters in SSc-ILD, comparing their performance with conventional spirometry. Methods: This study assessed the detection of the presence and severity of ILD in SSc patients using conventional spirometry, diffusing lung capacity for carbon monoxide (DLCO), IOS, and high-resolution CT (HRCT). Results: Among 66 SSc patients, ILD was identified in 62.1%, with 26 patients having extensive and 15 limited ILD on HRCT. IOS demonstrated higher mean resonant frequency (Fres) in ILD-positive patients than in ILD-negative patients (22.95 ± 5.47 vs 15.01 ± 6.01, P = 0.001). Fres was also significantly higher in extensive ILD than in limited ILD and ILD-negative groups (P = 0.001 and P = 0.011, respectively). ROC analysis demonstrated that Fres achieved comparatively better diagnostic accuracy for detecting extensive ILD [area under the curve (AUC): 0.841, cut-off: 22.35, sensitivity: 73.1%, specificity: 85%], outperforming forced vital capacity (FVC) (% predicted) and DLCO (% predicted). For limited ILD, Fres showed moderate diagnostic performance (AUC: 0.752, cut-off: 17.42, sensitivity: 80%, specificity: 64%). Conclusion: Our findings indicate that impulse oscillometry, particularly Fres, may provide a non-invasive and effort-independent approach to assessing interstitial lung disease in SSc. Fres appeared to be related to radiological ILD extent and showed some diagnostic value, including in cases less evident by conventional spirometry.
- 28 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Assessment of interstitial lung disease in systemic sclerosis using oscillometric methods: a novel approach to respiratory assessment
Objectives: Cardiopulmonary involvement is the leading cause of mortality in SSc, and early detection of interstitial lung disease (ILD) is critical to improving outcomes. Conventional spirometry has limitations, whereas impulse oscillometry (IOS) could provide a non-invasive, effort-independent method to detect and monitor pulmonary involvement in these patients. We aimed to evaluate IOS parameters in SSc-ILD, comparing their performance with conventional spirometry. Methods: This study assessed the detection of the presence and severity of ILD in SSc patients using conventional spirometry, diffusing lung capacity for carbon monoxide (DLCO), IOS, and high-resolution CT (HRCT). Results: Among 66 SSc patients, ILD was identified in 62.1%, with 26 patients having extensive and 15 limited ILD on HRCT. IOS demonstrated higher mean resonant frequency (Fres) in ILD-positive patients than in ILD-negative patients (22.95 ± 5.47 vs 15.01 ± 6.01, P = 0.001). Fres was also significantly higher in extensive ILD than in limited ILD and ILD-negative groups (P = 0.001 and P = 0.011, respectively). ROC analysis demonstrated that Fres achieved comparatively better diagnostic accuracy for detecting extensive ILD [area under the curve (AUC): 0.841, cut-off: 22.35, sensitivity: 73.1%, specificity: 85%], outperforming forced vital capacity (FVC) (% predicted) and DLCO (% predicted). For limited ILD, Fres showed moderate diagnostic performance (AUC: 0.752, cut-off: 17.42, sensitivity: 80%, specificity: 64%). Conclusion: Our findings indicate that impulse oscillometry, particularly Fres, may provide a non-invasive and effort-independent approach to assessing interstitial lung disease in SSc. Fres appeared to be related to radiological ILD extent and showed some diagnostic value, including in cases less evident by conventional spirometry.
- Open Access
- 13 June 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (9) , 2329-2336
Evolution of Clinical Characteristics and Treatment Strategies in Turkish SLE Patients Over Two Decades: A Retrospective Cohort Study
Objective: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with diverse patterns of organ involvement, morbidity, and mortality. This study aimed to assess changes in demographic, clinical, and therapeutic characteristics of a single-center SLE cohort over the last two decades. Materials and methods: This retrospective study included 409 SLE patients from the Rheumatology Department at Gazi University Faculty of Medicine, meeting the 2019 EULAR/ACR classification criteria. Patients were categorized by diagnosis year into two groups: 1987–2012 and 2013–2023. Results: The proportion of male SLE patients increased approximately 2.5-fold in the last decade (5.2% vs. 12.6%, p = 0.008). While lupus nephritis rates remained stable, neurological (p = 0.012), hematological (p < 0.001), pulmonary (p < 0.001), and gastrointestinal (p < 0.001) involvements were significantly higher in the last decade. Use of mycophenolate mofetil (p = 0.036), methotrexate (p < 0.001), calcineurin inhibitors (p < 0.001), and rituximab (p < 0.001) increased, while steroid use (p = 0.044) and flare frequency (p = 0.035) decreased significantly. Although crude mortality rates improved (4.7% vs. 3.5%) without statistical significance (p = 0.54), male patients exhibited higher mortality rates than females (13.8% vs. 3.2%, p = 0.011). Hospitalization rates decreased but were not statistically significant (0.00130 vs. 0.00104/patient/year, p = 0.855). Conclusion: Over the last two decades, SLE management has evolved with improved therapeutic approaches and changing clinical manifestations. However, mortality remains disproportionately higher in male patients, underscoring the need for targeted interventions.
- 13 June 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (9) , 2329-2336
Open AccessEvolution of Clinical Characteristics and Treatment Strategies in Turkish SLE Patients Over Two Decades: A Retrospective Cohort Study
Objective: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with diverse patterns of organ involvement, morbidity, and mortality. This study aimed to assess changes in demographic, clinical, and therapeutic characteristics of a single-center SLE cohort over the last two decades. Materials and methods: This retrospective study included 409 SLE patients from the Rheumatology Department at Gazi University Faculty of Medicine, meeting the 2019 EULAR/ACR classification criteria. Patients were categorized by diagnosis year into two groups: 1987–2012 and 2013–2023. Results: The proportion of male SLE patients increased approximately 2.5-fold in the last decade (5.2% vs. 12.6%, p = 0.008). While lupus nephritis rates remained stable, neurological (p = 0.012), hematological (p < 0.001), pulmonary (p < 0.001), and gastrointestinal (p < 0.001) involvements were significantly higher in the last decade. Use of mycophenolate mofetil (p = 0.036), methotrexate (p < 0.001), calcineurin inhibitors (p < 0.001), and rituximab (p < 0.001) increased, while steroid use (p = 0.044) and flare frequency (p = 0.035) decreased significantly. Although crude mortality rates improved (4.7% vs. 3.5%) without statistical significance (p = 0.54), male patients exhibited higher mortality rates than females (13.8% vs. 3.2%, p = 0.011). Hospitalization rates decreased but were not statistically significant (0.00130 vs. 0.00104/patient/year, p = 0.855). Conclusion: Over the last two decades, SLE management has evolved with improved therapeutic approaches and changing clinical manifestations. However, mortality remains disproportionately higher in male patients, underscoring the need for targeted interventions.
- Open Access
- 19 March 2025
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 137 (19-20) , 628-634
Lupus and IgA nephropathy: coexistence or coincident?
Summary: Background: Systemic lupus erythematosus is a multisystem autoimmune disease primarily manifesting as lupus nephritis. While lupus nephritis is the most common renal pathology in lupus, non-lupus nephropathies such as IgA nephropathy occasionally occur. This study aims to evaluate the clinical features and outcomes of lupus patients with IgA nephropathy, comparing them with those of primary IgA nephropathy and lupus nephritis. Methods: A comprehensive literature review was conducted using the PubMed and Google Scholar databases to identify cases of systemic lupus erythematosus with IgA nephropathy reported between 1995 and December 2023. A total of 16 cases were identified and 2 additional cases from our clinic were included. These cases were compared with 47 lupus nephritis patients from our clinic and 215 primary IgA nephropathy patients from the literature. Data were collected on demographics, serology, renal biopsy findings, treatment, progression to renal failure and mortality. Results: We identified 18 cases of lupus with IgA nephropathy with a median age of 41.6 years and a female predominance (72.2%). In comparison to the primary IgA nephropathy cohort, lupus with IgA nephropathy group exhibited a lower rate of renal failure (11.1% vs. 34%) and mortality (5.6% vs. 20%). Additionally, the lupus-IgA nephropathy group showed a slightly lower mortality rate compared to the lupus nephritis cohort (5.6% vs. 10.6%). Conclusion: Lupus with predominantly IgA deposits often follows a more indolent course than primary IgA nephropathy but severe cases with crescentic glomerulonephritis can still progress to renal failure.
- 19 March 2025
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 137 (19-20) , 628-634
Open AccessLupus and IgA nephropathy: coexistence or coincident?
Summary: Background: Systemic lupus erythematosus is a multisystem autoimmune disease primarily manifesting as lupus nephritis. While lupus nephritis is the most common renal pathology in lupus, non-lupus nephropathies such as IgA nephropathy occasionally occur. This study aims to evaluate the clinical features and outcomes of lupus patients with IgA nephropathy, comparing them with those of primary IgA nephropathy and lupus nephritis. Methods: A comprehensive literature review was conducted using the PubMed and Google Scholar databases to identify cases of systemic lupus erythematosus with IgA nephropathy reported between 1995 and December 2023. A total of 16 cases were identified and 2 additional cases from our clinic were included. These cases were compared with 47 lupus nephritis patients from our clinic and 215 primary IgA nephropathy patients from the literature. Data were collected on demographics, serology, renal biopsy findings, treatment, progression to renal failure and mortality. Results: We identified 18 cases of lupus with IgA nephropathy with a median age of 41.6 years and a female predominance (72.2%). In comparison to the primary IgA nephropathy cohort, lupus with IgA nephropathy group exhibited a lower rate of renal failure (11.1% vs. 34%) and mortality (5.6% vs. 20%). Additionally, the lupus-IgA nephropathy group showed a slightly lower mortality rate compared to the lupus nephritis cohort (5.6% vs. 10.6%). Conclusion: Lupus with predominantly IgA deposits often follows a more indolent course than primary IgA nephropathy but severe cases with crescentic glomerulonephritis can still progress to renal failure.
- Open Access
- 1 January 2025
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2025 (1)
Intersecting Pathways: Moyamoya Syndrome and Antiphospholipid Antibodies—A Comprehensive Review of Clinical Insights, Therapeutic Considerations and Prospective Perspectives
Background/Aim: Moyamoya disease, a rare cerebrovascular disorder first identified in Japan, is characterised by spontaneous occlusion of the circle of Willis and is a significant cause of ischaemic and haemorrhagic strokes. When associated with autoimmune disorders like antiphospholipid syndrome, it is referred to as moyamoya syndrome. This study reviews the clinical features of moyamoya syndrome in patients with antiphospholipid antibody positivity, with and without antiphospholipid syndrome, focusing on clinical differences, treatments and outcomes. Methods: To identify relevant studies, a comprehensive systematic literature review search was conducted using the terms ‘Moyamoya’, ‘antiphospholipid’, ‘anticardiolipin antibodies’, ‘anti‐beta2‐glycoprotein I antibodies’ and ‘lupus anticoagulant’. Results: Twelve cases of moyamoya syndrome with antiphospholipid antibody positivity were reviewed. Eight met antiphospholipid syndrome criteria with diverse antibody profiles. Treatments included antiplatelet therapy, anticoagulants and bypass surgery. While eight patients experienced no recurrent strokes during follow‐up, three had recurrent strokes, and two died from haemorrhagic events. Individualised management was crucial for balancing treatment benefits and risks. Discussion: Moyamoya disease involves internal carotid artery stenoses, also seen in antiphospholipid syndrome. While the connection between moyamoya disease and antiphospholipid antibody positivity remains unclear, antiphospholipid syndrome should be ruled out during diagnosis. Surgical treatments are less frequent in antiphospholipid antibody‐positive patients than in general moyamoya disease. Recurrent cerebrovascular events under medical treatment highlight the potential need for broader surgical interventions in these patients. Conclusion: The limited number of reported cases restricts the generalisability of the current findings and calls for cautious interpretation. This underlines the need for further multicentre studies and randomised trials to optimise therapeutic strategies, elucidate the role of antiphospholipid antibodies and establish evidence‐based guidelines for the management of moyamoya syndrome and its variants.
- 1 January 2025
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2025 (1)
Open AccessIntersecting Pathways: Moyamoya Syndrome and Antiphospholipid Antibodies—A Comprehensive Review of Clinical Insights, Therapeutic Considerations and Prospective Perspectives
Background/Aim: Moyamoya disease, a rare cerebrovascular disorder first identified in Japan, is characterised by spontaneous occlusion of the circle of Willis and is a significant cause of ischaemic and haemorrhagic strokes. When associated with autoimmune disorders like antiphospholipid syndrome, it is referred to as moyamoya syndrome. This study reviews the clinical features of moyamoya syndrome in patients with antiphospholipid antibody positivity, with and without antiphospholipid syndrome, focusing on clinical differences, treatments and outcomes. Methods: To identify relevant studies, a comprehensive systematic literature review search was conducted using the terms ‘Moyamoya’, ‘antiphospholipid’, ‘anticardiolipin antibodies’, ‘anti‐beta2‐glycoprotein I antibodies’ and ‘lupus anticoagulant’. Results: Twelve cases of moyamoya syndrome with antiphospholipid antibody positivity were reviewed. Eight met antiphospholipid syndrome criteria with diverse antibody profiles. Treatments included antiplatelet therapy, anticoagulants and bypass surgery. While eight patients experienced no recurrent strokes during follow‐up, three had recurrent strokes, and two died from haemorrhagic events. Individualised management was crucial for balancing treatment benefits and risks. Discussion: Moyamoya disease involves internal carotid artery stenoses, also seen in antiphospholipid syndrome. While the connection between moyamoya disease and antiphospholipid antibody positivity remains unclear, antiphospholipid syndrome should be ruled out during diagnosis. Surgical treatments are less frequent in antiphospholipid antibody‐positive patients than in general moyamoya disease. Recurrent cerebrovascular events under medical treatment highlight the potential need for broader surgical interventions in these patients. Conclusion: The limited number of reported cases restricts the generalisability of the current findings and calls for cautious interpretation. This underlines the need for further multicentre studies and randomised trials to optimise therapeutic strategies, elucidate the role of antiphospholipid antibodies and establish evidence‐based guidelines for the management of moyamoya syndrome and its variants.
- Open Access
- 3 August 2022
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 10 (1) , 29-33
Dual Biologic Therapy in Patients with Familial Mediterranean Fever and Spondyloarthritis: Case-Based Review
Patients with familial Mediterranean fever and spondylitis often fail to respond to conventional and biologic therapies. Achieving remission in these patients usually requires conventional and biologic treatment combinations. Combination of biologic agents may be a promising option for patients with familial Mediterranean fever and spondylitis who have refractory disease. Until recently, limited evidence existed regarding the efficacy and safety of this treatment strategy. To address this, our report presented a case series of 4 patients with familial Mediterranean fever and spondylitis who were resistant to standard treatments and in whom remission is achieved only with dual biologic therapy. The authors also conducted a literature search for studies that reported dual biological therapy in inflammatory diseases. Cite this article as: Yıldırım D, Kardaş RC, Özkızıltaş B, et al. Dual biologic therapy in patients with familial mediterranean fever and spondyloarthritis: case-based review. Eur J Rheumatol 2023;10(1):29-33.
- 3 August 2022
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 10 (1) , 29-33
Open AccessDual Biologic Therapy in Patients with Familial Mediterranean Fever and Spondyloarthritis: Case-Based Review
Patients with familial Mediterranean fever and spondylitis often fail to respond to conventional and biologic therapies. Achieving remission in these patients usually requires conventional and biologic treatment combinations. Combination of biologic agents may be a promising option for patients with familial Mediterranean fever and spondylitis who have refractory disease. Until recently, limited evidence existed regarding the efficacy and safety of this treatment strategy. To address this, our report presented a case series of 4 patients with familial Mediterranean fever and spondylitis who were resistant to standard treatments and in whom remission is achieved only with dual biologic therapy. The authors also conducted a literature search for studies that reported dual biological therapy in inflammatory diseases. Cite this article as: Yıldırım D, Kardaş RC, Özkızıltaş B, et al. Dual biologic therapy in patients with familial mediterranean fever and spondyloarthritis: case-based review. Eur J Rheumatol 2023;10(1):29-33.